ACELYRIN, a late-stage biotech developing acquired therapies for inflammatory diseases, filed on Thursday with the SEC to raise up to $100 million in an initial public offering.
ACELYRIN's initial focus is on the treatment of diseases with pathology related to excess activation of the immune system, acquiring its portfolio of candidates with the intent to develop and commercialize novel therapies that it believes may provide the opportunity to offer clinically meaningful, differentiated benefits for patients. Its lead candidate, izokibep, is a small protein therapeutic designed to inhibit IL-17A. The candidate is currently in Phase 2b/3 trials for hidradenitis suppurativa, psoriatic arthritis, and uveitis.
The Agoura Hills, CA-based company was founded in 2020 and plans to list on the Nasdaq under the symbol SLRN. Morgan Stanley, Jefferies, TD Cowen, and Piper Sandler are the joint bookrunners on the deal. No pricing terms were disclosed.
